Cantourage, a Berlin-based cannabis producer and distributor, is experiencing significant growth as the medical cannabis market thrives in Germany. The company operates under the motto ‘we love cannabis’ and is publicly traded on the Frankfurt Stock Exchange under the ticker symbol ‘HIGH’.
During a recent visit to one of its facilities in Bavaria, CEO Philip Schetter showcased the security measures in place for their operations, including a robust 75-centimetre (30-inch) thick steel door that protects large quantities of cannabis. ‘Better safe than sorry,’ Schetter stated, emphasizing the importance of security in the cannabis industry.
Germany’s medical cannabis market has expanded rapidly since its legalization in 2017, allowing prescriptions for cannabis-based therapies. Patients now have access to various products, including oils and dried flowers, as the demand for alternative treatments continues to rise.
Cantourage’s strategy includes not only cultivation but also the distribution of cannabis-based medicines to pharmacies across the country. The company’s growth trajectory reflects a broader trend in the industry, as more healthcare providers recognize the therapeutic potential of cannabis.
The firm has also invested in research and development to improve product offerings and ensure compliance with regulatory standards. This focus on quality and safety is essential in a sector where consumer trust is paramount.
As the medical cannabis sector matures, companies like Cantourage are positioning themselves to meet the increasing demand, while navigating the evolving regulatory landscape in Germany. The future looks promising for this industry as it continues to gain acceptance both among patients and healthcare professionals.
English 
Spanish 
German 
Czech